News
GALT
3.290
-2.66%
-0.090
Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage
Madrigal Pharmaceuticals, Inc. Recently received FDA approval for its lead candidate resmetirom, targeting a liver condition called NASH. The NASH market is projected to reach $50 billion by 2035. The company will have to overcome two challenges to maintain its "first mover" advantage in the market. Madrigal has to manage the launch of Rezdiffra and keep an eye on future competitors.
Seeking Alpha · 13h ago
Galectin Therapeutics And 2 Other Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. The Dow Jones index closed higher by over 250 points on Monday. Recent notable insider transactions for penny stocks include Mobile Infrastructure Corp and Galectin Therapeutics Inc. Mobile Infrastructure CEO Manuel Chavez III acquired 55,000 shares for $186,000.
Benzinga · 1d ago
Weekly Report: what happened at GALT last week (0415-0419)?
Weekly Report · 2d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 5d ago
Weekly Report: what happened at GALT last week (0408-0412)?
Weekly Report · 04/15 12:20
Wall Street Breakfast: The Week Ahead
Geopolitical tensions in the Middle East will hold the focus of markets to start the week after Iran's attack on Israel. The economic calendar will continue to garner attention with retail sales and industrial production on the docket. The first quarter earnings season will pick up pace next week.
Seeking Alpha · 04/14 11:51
Catalyst Watch: Boeing hearing, Bitcoin halving event and new eyes on Reddit
Seeking Alpha's Catalyst Watch looks at events that may impact stock prices next week. The Bitcoin halving event will be a major focus in the cryptocurrency world. Options trading volume is elevated on electric vehicle stocks Nikola and Rivian. The four-day NAB Show in Las Vegas will focus on cybersecurity and the role of AI in media.
Seeking Alpha · 04/12 19:00
Rating the Top 4 Unusually Active Call Options From Thursday’s Trading
Friday is the final day of the trading week. The major indexes are down more than 1% and the Dow is at a two-month low. Thursday's options trading saw unusual activity. Frontdoor Frontdoor was one of four unusually active call options on Thursday. Galectin Therapeutics and KKR & Co. Are two companies that are in good shape heading into earnings.
Barchart · 04/12 12:00
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Inogen (INGN) and Galectin Therapeutics (GALT)
TipRanks · 04/09 16:10
Galectin Therapeutics Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 04/09 16:08
HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target
Benzinga · 04/09 15:57
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Healthcare Madrigal announces US launch of NASH/MASH drug Rezdiffra. The drug is now available in the US through a specialty pharmacy network. Other companies working on therapies for NASH and MASH include Eli Lilly and Novo Nordisk. MadrigAL is the first to receive FDA approval for the treatment of the disease.
Seeking Alpha · 04/09 14:03
Galectin Therapeutics Highlights Outcome Of Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study
Benzinga · 04/09 13:26
GALECTIN THERAPEUTICS REPORTS THE POSITIVE OUTCOME OF THE FIFTH DATA AND SAFETY MONITORING BOARD MEETING FOR NAVIGATE PHASE 2B/3 STUDY OF BELAPECTIN IN PATIENTS WITH CIRRHOTIC PORTAL HYPERTENSION CAUSED BY METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS
Reuters · 04/09 12:05
Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare movers
Galectin Therapeutics, Titan Pharmaceuticals, Outset Medical among healthcare movers. S&P 500 Health Care Sector -0.3% to 1665.92. Pharmaceuticals and Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 04/08 14:00
Weekly Report: what happened at GALT last week (0401-0405)?
Weekly Report · 04/08 12:26
12 Health Care Stocks Moving In Friday's Intraday Session
Candel Therapeutics (NASDAQ:CADL) stock increased by 27.6% to $8.17 during Friday's regular session. The company's market cap stands at $239.6 million. Galectin Therapeutic shares increased by 20.66% and Ocugen stock moved upwards by 17.88%. Candel Therapeutical is one of the top gainers in the sector.
Benzinga · 04/05 16:31
GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023
Galectin Therapeutics reported earnings per share of -16 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This met the analyst estimate for EPS of -15 cents. GalectinTherapeutics just reported results.
Investorplace · 04/05 12:52
Buy Rating Affirmed for Galectin Therapeutics Amidst Positive Clinical Trial Progress and Enhanced Financial Stability
TipRanks · 04/01 16:25
Weekly Report: what happened at GALT last week (0325-0329)?
Weekly Report · 04/01 12:22
More
Webull provides a variety of real-time GALT stock news. You can receive the latest news about Galectin Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About GALT
Galectin Therapeutics, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company's lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the United States Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.